Understanding how genetic factors affect responses to antibody treatments and vaccines
Host Factors in Response to Therapeutic Monoclonal Antibodies and Vaccination
['FUNDING_U01'] · UNIVERSITY OF ALABAMA AT BIRMINGHAM · NIH-10760257
This study is looking at how your unique genes might affect how well certain antibody treatments and vaccines work for you, so we can better understand why some people don’t respond as well and find ways to make treatments more personalized and effective.
Quick facts
| Phase | ['FUNDING_U01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF ALABAMA AT BIRMINGHAM (nih funded) |
| Locations | 1 site (BIRMINGHAM, UNITED STATES) |
| Trial ID | NIH-10760257 on ClinicalTrials.gov |
What this research studies
This research investigates how individual genetic differences influence the effectiveness of therapeutic monoclonal antibodies and vaccinations. By examining the interactions between specific Fc receptors on immune cells and these treatments, the study aims to identify why some patients do not respond effectively. The researchers will utilize advanced genetic techniques, including CRISPR/Cas9 and linked-reads sequencing, to uncover structural variations in genes that may impact treatment outcomes. This work could lead to more personalized approaches in immunotherapy and vaccination strategies.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals receiving monoclonal antibody treatments or vaccinations who may have varying responses due to genetic factors.
Not a fit: Patients who are not undergoing antibody treatments or vaccinations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies that enhance the effectiveness of antibody therapies and vaccines for patients.
How similar studies have performed: Other research has shown promise in understanding genetic influences on treatment responses, making this approach both relevant and potentially impactful.
Where this research is happening
BIRMINGHAM, UNITED STATES
- UNIVERSITY OF ALABAMA AT BIRMINGHAM — BIRMINGHAM, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KIMBERLY, ROBERT P. — UNIVERSITY OF ALABAMA AT BIRMINGHAM
- Study coordinator: KIMBERLY, ROBERT P.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.